货号:GS40130
Cifurtilimab (SEA-CD40) is an investigational humanized anti-CD40 IgG1 monoclonal antibody developed as an immune-activating therapy for cancer. It functions as a CD40 agonist, designed to directly activate a key receptor on immune cells to enhance the body's anti-tumor immune response. Its proposed mechanisms of action include stimulating antigen-presenting cells (APCs) and B cells, as well as inducing antibody-dependent cellular cytotoxicity (ADCC) against CD40-positive tumor cells. The drug is currently in clinical trials for various solid tumors, including melanoma and non-small cell lung cancer (NSCLC).
武汉迈思生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
迈思生物